Chancery Upholds AbbVie Damages In Takeda-Lupron Suit
Delaware's Court of Chancery on Tuesday largely upheld AbbVie's $480.7 million damage request in its dispute with Takeda Pharmaceutical Co. Ltd. over 2019 supply disruptions of the cancer drug Lupron Depot,...To view the full article, register now.
Already a subscriber? Click here to view full article